Enavatuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | TWEAK receptor |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6334H9792N1700O2000S42 |
| Molar mass | 143104.43 g·mol−1 |
| (what is this?) (verify) | |
Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors. It targets the TWEAK receptor.
Enavatuzumab was developed by Facet Biotech Corp.